BTIG Maintains Buy Rating for Verona Pharma: Here's What You …

Dec 20, 2022 · BTIG has decided to maintain its Buy rating of Verona Pharma (NASDAQ:VRNA) and raise its price target from $17.00 to $26.00. Shares of Verona Phar...

$17.00
OFF

BTIG Maintains Buy Rating For Verona Pharma: Here's What You …

2 weeks from now

Dec 20, 2022 · BTIG has decided to maintain its Buy rating of Verona Pharma (NASDAQ:VRNA) and raise its price target from $17.00 to $26.00. Shares of Verona Phar...

businessinsider.com

$77
OFF

Verona Pharma Price Target Raised To $77 From $51 At BTIG

2 weeks from now

Jan 8, 2025 · BTIG raised the firm’s price target on Verona Pharma to $77 from $51 and keeps a Buy rating on the shares.The company’s Q4 pre-announcement was “impressive”, with …

businessinsider.com

$31.00
OFF

BTIG Remains A Buy On Verona Pharma (VRNA) | Markets Insider

2 weeks from now

May 31, 2023 · BTIG analyst Thomas Shrader maintained a Buy rating on Verona Pharma (VRNA – Research Report) yesterday and set a price target of $31.00. ...

businessinsider.com

$77
OFF

Verona Pharma Stock Target Increased, Keeps Buy On Q4 Sales

2 weeks from now

Jan 8, 2025 · Reiterate BUY." The company maintains impressive gross profit ... BTIG analysts recently raised Verona Pharma's stock target to $77, citing the early-stage launch of …

investing.com

34%
OFF

Verona Pharma Stock Target Increased, Keeps Buy On Q4 Sales

2 weeks from now

Jan 8, 2025 · Reiterate BUY." The company maintains impressive gross profit margins of 90.34% and operates with a moderate ... Verona Pharma has been under the spotlight due to several …

investing.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG

2 weeks from now

Jan 7, 2025 · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

$26
OFF

BTIG Boosts Price Target On Verona Pharma To $26 From $17, …

2 weeks from now

-- Verona Pharma has an average rating of buy and price targets ranging from $17 to $31, according to analysts polled by Capital IQ. Price: 17.80, Change: +4.31, Percent Change: …

marketscreener.com

$31
OFF

BTIG Adjusts Price Target On Verona Pharma To $31 From $26, …

2 weeks from now

-- Verona Pharma has an average buy rating and a price target range of $28 to $35, according to analysts polled by Capital IQ. Price: 19.05, Change: +0.45, Percent Change: +2.42 ...

marketscreener.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com …

2 weeks from now

In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations and a …

investing.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com

2 weeks from now

Jan 7, 2025 · Verona Pharma stock target raised to $77 at BTIG. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing …

investing.com

$77
OFF

Verona Pharma Stock Target Raised To $77 At BTIG

2 weeks from now

Jan 7, 2025 · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

$31
OFF

BTIG Maintains Buy On Verona Pharma, Raises Price Target To $31

2 weeks from now

BTIG Maintains Buy on Verona Pharma, Raises Price Target to $31. Benzinga · 03/20/2023 13:44. BTIG analyst Thomas Shrader maintains Verona Pharma (NASDAQ:VRNA) with a Buy …

webull.com

$31.00
OFF

BTIG Keeps Their Buy Rating On Verona Pharma (VRNA)

2 weeks from now

Jan 7, 2024 · BTIG analyst Thomas Shrader maintained a Buy rating on Verona Pharma (VRNA – Research Report) on January 5 and set a price target of $31.00.The company’s shares closed …

businessinsider.com

$31.00
OFF

Verona Pharma (VRNA) Gets A Buy From BTIG | Markets Insider

2 weeks from now

May 10, 2023 · BTIG analyst Thomas Shrader maintained a Buy rating on Verona Pharma (VRNA – Research Report) yesterday and set a price target of $31.00. ...

businessinsider.com

$31
OFF

BTIG Reaffirms Their Buy Rating On Verona Pharma (VRNA)

2 weeks from now

Dec 31, 2023 · BTIG analyst Thomas Shrader maintained a Buy rating on Verona Pharma (VRNA – Research Report) on December 28 and set a price target of $31...

businessinsider.com

$34.00
OFF

Buy Rating On Verona Pharma: Promising Launch And Strong …

2 weeks from now

Aug 9, 2024 · In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $34.00. Thomas Shrader …

businessinsider.com

$51.00
OFF

Truist Financial Issues A Buy Rating On Verona Pharma (VRNA)

2 weeks from now

Nov 13, 2024 · In a report released on November 5, BTIG also maintained a Buy rating on the stock with a $51.00 price target. See the top stocks recommended by analysts >> VRNA …

businessinsider.com

FAQs about BTIG Maintains Buy Rating for Verona Pharma: Here's What You … Coupon?

Is Verona Pharma a good stock to buy?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $43.86 average price target, which is a 14.97% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $45.00 price target. ...

Should you buy Lee & Verona Pharma?

According to TipRanks, Lee has an average return of 29.8% and a 55.24% success rate on recommended stocks. Verona Pharma has an analyst consensus of Strong Buy, with a price target consensus of $47.00, implying a 20.51% upside from current levels. ...

Is Verona Pharma (vRNA) a sustainable investment?

Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable Zacks Equity Research Fri, Jan 10, 2025, 5:50 AM3 min read In This Article: VRNA When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. ...